Pharscin Pharma

Focus on FIC & BIC Drug Development for Oncology and Autoimmune Diseases Asset ORIP-1001 (Phase Ib): First RIPK1 inhibitor for hemophagocytic lymphohistiocytosis (HLH)

Target Discovery＆Validation Platform

Target‑Structure‑Based Medicinal Chemistry Design & Synthesis Platform‍

In Vivo Pharmacodynamic ＆ Early Toxicology Platform‍‍

In Vitro Biological Research Platform‍‍

‍CMC Development Platform‍

Target‑Structure‑Based Medicinal Chemistry Design & Synthesis Platform‍

In 2021, the Testing Center of Pharscin Pharma was awarded the Laboratory Accreditation Certificate by CNAS becoming the first pharmaceutical company in Chongqing to achieve this recognition. Its testing results are mutually recognized in over 100 countries and regions worldwide, including the US, UK, Japan, and the EU. This ensures that the quality of Pharscin's products benchmarks against international standards, marking that the company has established a quality management system that meets advanced global standards.